The federal judge handling the multidistrict litigation against GlaxoSmithKline over its drug Avandia denied the bid for class certification made by an insurer trying to recoup the costs it paid to cover the illnesses allegedly caused by Avandia.
U.S. District Judge Cynthia Rufe of the Eastern District of Pennsylvania held that individual issues for each of the dozens of insurers would predominate over any issues that would be common among them, so class certification wouldn’t be appropriate.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
